Annual report pursuant to Section 13 and 15(d)

Supplemental Balance Sheet and Cash Flow Information (Tables)

Supplemental Balance Sheet and Cash Flow Information (Tables)

12 Months Ended

Jun. 30, 2022

Schedule of Inventory, Current [Table Text Block]

Inventories consist of (in thousands):


	June 30,
	2022		2021

Raw materials	$	79,291	$	55,096
Finished goods⁽¹⁾		66,943		67,108
Inventories, net	$	146,234	$	122,204

(1)	Finished goods inventory of $5,111 and $5,456 is included within other long-term assets in the June 30, 2022 and June 30, 2021 Balance Sheets, respectively, as it forecasted to be sold after the 12 months subsequent to the consolidated balance sheet date.

Property, Plant and Equipment [Table Text Block]

Property and equipment consist of (in thousands):


	June 30,
	2022		2021
Cost:
Land	$	8,572	$	8,612
Buildings and improvements		229,551		190,661
Machinery and equipment		174,813		149,410
Construction in progress		21,729		49,073
Property and equipment, cost		434,665		397,756
Accumulated depreciation and amortization		(211,423)		(189,849)
Property and equipment, net	$	223,242	$	207,907

Schedule of Intangible Assets and Goodwill [Table Text Block]

Intangibles assets were comprised of the following (in thousands):


	Useful Life	June 30,
	(years)	2022		2021

Developed technology	9 - 15	$	542,038	$	552,160
Trade names	2 - 20		146,457		147,640
Customer relationships	7 - 16		225,882		232,493
Patents	10		3,313		2,926
Other intangibles	5 - 15		6,306		6,316
Definite-lived intangible assets			923,996		941,535
Accumulated amortization			(415,174)		(348,267)
Definite-lived intangibles assets, net			508,822		593,268
In process research and development			22,700		22,700
Total intangible assets, net		$	531,522	$	615,968

Schedule of Finite-Lived Intangible Assets [Table Text Block]

Changes to the carrying amount of net intangible assets consist of (in thousands):


	June 30,
	2022		2021

Beginning balance	$	615,968	$	516,545
Acquisitions		—		153,311
Other additions		293		5,912
Amortization expense		(74,147)		(64,940)
Currency translation		(2,029)		5,140
Eminence impairment ⁽¹⁾		(8,563)		—
Ending balance	$	531,522	$	615,968

⁽¹⁾ As disclosed in Note 1, the Company recorded an impairment charge of $8.6 million related to Eminence in Q2 of fiscal 2022.

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

The estimated future amortization expense for intangible assets as of June 30, 2022, excluding any possible future amortization associated with acquired IPR&D which has not met technological feasibility, is as follows (in thousands):


2023	$	71,366
2024		68,702
2025		65,266
2026		61,689
2027		51,771
Thereafter		190,028
Total	$	508,822

Schedule of Goodwill [Table Text Block]

Changes in goodwill by segment and in total consist of (in thousands):


			Diagnostics and
	Protein Sciences		Genomics		Total
June 30, 2020	$	373,081	$	355,229	$	728,310
Acquisitions (Note 4)		7,848		94,970		102,818
Currency translation		11,788		151		11,939
June 30, 2021	$	392,717	$	450,350	$	843,067
Acquisitions⁽¹⁾		—		(4,407)		(4,407)
Eminence impairment		(8,275)		—		(8,275)
Currency translation		(7,949)		(335)		(8,284)
June 30, 2022	$	376,493	$	445,608	$	822,101

⁽¹⁾As discussed in Note 4, there was an adjustment to the preliminary allocation of the Asuragen acquisition opening balance sheet during the measurement period.

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

Supplemental cash flow information was as follows (in thousands):


	Year Ended June 30,
	2022		2021		2020
Income taxes paid	$	30,341	$	20,952	$	41,992
Interest paid		11,027		13,576		18,615
Non-cash activities:
Acquisition-related liabilities(1)		20,400		23,600		(2,105)
Other intangibles(2)		—		4,000		—

(1)

Consists of holdback payments due at future dates and liabilities for contingent consideration. Amounts disclosed above represent the total non-cash change in the liability from the prior fiscal year. Further information regarding liabilities for contingent consideration can be found in Notes 4 and 5.

(2)	$4.0 million of the third party patented technology acquired in fiscal 2021 was a non-cash activity within the consolidated statement of cash flows as a cash payment was not made within the fiscal year ended June 30, 2021.